Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Among 166 patients with CR by the end of induction receiving maintenance (quizartinib, n = 94; placebo, n = 72), RFS rates trended higher at 1, 2, and 3 years with quizartinib vs placebo ( Figure 2 B), but these differences did not reach statistical significance.

also in 111,027 other papers

Sensitivity analyses of EFS, without the day-42 restriction, showed a trend toward EFS improvement with quizartinib, with an HR of 0.786 (95% CI, 0.532-1.162) when ITF was defined as not achieving CR, and an HR of 0.760 (95% CI, 0.490-1.179) when ITF was defined as not achieving CRc.

also in 53,322 other papers